logo
Trouble Falling Asleep? I Tried This Viral Sleepy Girl Mocktail and the Results Surprised Me

Trouble Falling Asleep? I Tried This Viral Sleepy Girl Mocktail and the Results Surprised Me

CNET3 days ago
My team of CNET sleep experts and I are always looking for the best ways of getting a good night's sleep. Between testing mattresses and researching melatonin supplements, we make time to fact-check viral social media videos. Naturally, when the "Sleepy Girl Mocktail" made its rounds on TikTok and Instagram last year, I had to test its claim of being a sleep-aid-free drink by trying it for myself.
A week before I sat down to write this article, when the drink first became popular, I went to the store in search of the ingredients. Down the juice aisle at my local Publix, each shelf was stocked with rows of cranberry, apple, beet, tomato, various V8 and prune juice. But when I reached the organic juice shelf, an entire section was completely empty. The tart cherry juice was gone.
Read more: Replace Melatonin With These 7 Popular All-Natural Sleep Aids
The tart cherry juice was flying off the shelves.
Caroline Igo/CNET
This isn't a one-off experience. This seems to happen whenever there's a new viral TikTok trend. Whether it's fashion or an intriguing skincare trend, TikTok drives people in waves to new products. Not all TikTok trends are safe -- take the Nyquil Chicken videos, for example. So, is the "sleepy girl mocktail" even a good idea?
I've been writing about all things sleep for years now. Here's a sleep expert's take on the Sleepy Girl Mocktail, and if I think it's worth stalking your local grocery store for new shipments of tart cherry juice.
What is the Sleepy Girl Mocktail?
While the original creator, Gracie Norton, first posted the Sleepy Girl Mocktail recipe in March of 2023, the trend seemed to pick up again around Dry January. TikTok creators were sharing their favorite mocktail recipes, and this brought the Sleepy Girl Mocktail back into the conversation. While the mocktail looks like an everyday non-alcoholic drink, its ingredients encourage restful sleep.
This drink is simple to make. First, start with a glass -- this could be a cocktail glass, a wine glass or an ordinary glass -- and fill it with about half a cup of tart cherry juice. It's important to get tart cherry juice that's not full of added sugar; it should be 100% pure cherry juice, ideally not from concentrate. Then, mix in about a teaspoon to a tablespoon of magnesium powder and top it off with ice and sparkling water or a soda of your choice. Creators tend to use prebiotic soda -- Olipop or Poppi are options we've seen -- which contain less sugar and have some gut-friendly benefits.
These measurements are not exact. You can add as much cherry juice or sparkling water as you like. It's important to follow the recommended serving size of your chosen magnesium supplement, as some people may react to too much magnesium initially.
Sleepy Girl Mocktail ingredients
Ice
Half a cup of tart cherry juice
A teaspoon to a tablespoon of magnesium powder
Sparkling water or soda (usually Olipop Poppi
How does tart cherry juice help you sleep?
While all cherries contain small amounts of melatonin, tart cherries seem to contain more and may even improve your sleep quality and insomnia. According to a 2018 study exploring the effects of tart cherry juice on insomnia, the juice contained tryptophan that increased sleep time and sleep efficiency in insomnia patients. Tryptophan, also found in foods like turkey and whole milk, is an amino acid that helps the body make melatonin. In layman's terms, tart cherry juice contains naturally occurring amino acids that help tell the body when it is time to go to sleep.
How does magnesium help you sleep?
Tart cherry juice isn't the only sleep-inducing ingredient in the Sleepy Girl Mocktail. The added magnesium supplements also have an impact on sleep. Magnesium is an essential mineral that the body uses to support the immune system, produce energy, maintain healthy bones and muscles and even keep the heartbeat regular. There are over 300 biochemical functions throughout the body that require magnesium. In addition, magnesium may aid in calming your nervous system and possibly reduce cortisol levels in the body. It may also increase melatonin production in the body. Studies have shown that it can increase sleep and help those having difficulty falling asleep.
What type of magnesium is best for sleep?
When choosing your magnesium supplement for your Sleepy Girl Mocktail, there are a few options. Magnesium glycinate is best for sleeping. This type aids in relaxation and is easily absorbed into the body. Try to steer clear of magnesium oxide, because that is used mainly to relieve constipation.
My experience with the viral sleep trend
Since I live close to a grocery store, I checked nearly every day for tart cherry juice to come back in stock. A week passed and either I missed it or TikTok had cleared out my local Publix of all tart cherry juice for the foreseeable future. I begrudgingly ended up buying a bottle on Amazon instead (it's cheaper to buy in-store). Once my Amazon package arrived, I was finally able to try out a Sleepy Girl Mocktail for myself.
Caroline Igo/CNET
I made my first mocktail about an hour and a half before bed. I first took two capsules of magnesium -- since I didn't have any powdered magnesium -- and got out a wine glass and ingredients. I poured about half of a cup of organic tart cherry juice into my glass and filled it up with ice. Lastly, I topped it off with an orange-flavored Poppi. It tasted like a fruit punch.
Despite its name, the cherry juice is sweet. I was expecting it to taste similar to bitter, like pure cranberry juice -- which I often drink (mixed with water) for its health benefits. Tart cherry juice reminds me of the sweetness of grape juice. It mixes well with the flavored Poppi that I chose, as I imagine it would with any fruit-flavored drink.
While I can't speak to how it tastes with powdered magnesium, the sleepy mocktail did taste like a mocktail. It was sweet and pleasant. I was surprised to find that it was even a bit too sweet for me, especially right before bed. I'm someone who chooses savory over sweet, so it might be the perfect amount of sweetness for someone else.
About 30 minutes later, I felt tired. It felt like I'd taken 5 mg of melatonin and was ready for bed. I immediately fell asleep that night.
Does the Sleepy Girl Mocktail work?
Caroline Igo/CNET
The Sleepy Girl Mocktail really did help me fall asleep. Its two main ingredients -- tart cherry juice and magnesium -- have been scientifically proven to induce sleepiness. Tart cherry juice increases melatonin production, and magnesium decreases cortisol, promotes relaxation and sleep and regulates GABA production in the brain. You don't necessarily need to mix the two to feel the effects. You can take one without the other and vice versa. Together, the ingredients are a safe, effective and natural sleep aid.
While I found the mocktail too sweet to drink every night, I plan on swapping the Poppi for seltzer water. That should help cut back on the sugar. If you don't want to spike your blood sugar before bed, herbal teas, especially those containing chamomile or valerian root, are a good alternative. Herbal tea is another natural sleep aid, and chamomile and valerian root have been proven to promote relaxation and sleep.
Overall, the Sleepy Girl Mocktail is a simple drink that anyone can enjoy. If you don't want to take a melatonin supplement at night, this easy and natural sleep aid could suit you. Talk to your doctor before mixing any medications, such as blood pressure medications, with tart cherry juice.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vistagen to Present at the BTIG Virtual Biotechnology Conference
Vistagen to Present at the BTIG Virtual Biotechnology Conference

Yahoo

time16 minutes ago

  • Yahoo

Vistagen to Present at the BTIG Virtual Biotechnology Conference

SOUTH SAN FRANCISCO, Calif., July 24, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be livestreamed for registered investors, and a recording will be available on the BTIG conference portal for conference attendees following the event. If you would like to schedule a one-on-one meeting with Vistagen's management team, please contact your BTIG representative. To join the conference, email uscorporateaccess@ About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, such as vasomotor symptoms (hot flashes) associated with menopause. Connect at View source version on Contacts Investor Inquiries: Mark A. McPartlandmarkmcp@ Media Inquiries: Michelle P. Wellingtonmwellington@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

What to Expect From Insulet's Q2 2025 Earnings Report
What to Expect From Insulet's Q2 2025 Earnings Report

Yahoo

time16 minutes ago

  • Yahoo

What to Expect From Insulet's Q2 2025 Earnings Report

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued at $20.2 billion by market cap, the company develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The insulin infusion systems maker is expected to announce its fiscal second-quarter earnings for 2025 before the market opens on Thursday, Aug. 7. Ahead of the event, analysts expect PODD to report a profit of $0.93 per share on a diluted basis, up 69.1% from $0.55 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect PODD to report EPS of $4.33, up 33.6% from $3.24 in fiscal 2024. Its EPS is expected to rise 25.4% year over year to $5.43 in fiscal 2026. PODD stock has outperformed the S&P 500 Index's ($SPX) 14.5% gains over the past 52 weeks, with shares up 45.7% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 8.3% dip over the same time frame. Insulet's strong performance is driven by robust U.S. growth, expanding international demand, and the success of its Omnipod insulin delivery systems. With continued innovation and global expansion, the company is well-positioned for long-term growth in the diabetes care market, making it a promising investment in the medical technology sector. On May 8, PODD reported its Q1 results, and its shares closed up more than 20% in the following trading session. Its adjusted EPS of $1.02 surpassed Wall Street's expectations of $0.81. The company's revenue was $569 million, topping Wall Street forecasts of $542.1 million. Analysts' consensus opinion on PODD stock is bullish, with an overall 'Strong Buy' rating. Out of 23 analysts covering the stock, 19 advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' and two give a 'Hold.' PODD's average analyst price target is $343.77, indicating a potential upside of 19.9% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio

Agilent Technologies' Q3 2025 Earnings: What to Expect
Agilent Technologies' Q3 2025 Earnings: What to Expect

Yahoo

time16 minutes ago

  • Yahoo

Agilent Technologies' Q3 2025 Earnings: What to Expect

Santa Clara, California-based Agilent Technologies, Inc. (A) is a global leader in providing application-focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at a market cap of $33.9 billion, the company designs and manufactures a broad portfolio of analytical instruments, software, consumables, and services. It is scheduled to announce its fiscal Q3 earnings for 2025 after the market closes on Wednesday, Aug. 27. Before this event, analysts project this healthcare company to report a profit of $1.37 per share, up 3.8% from $1.32 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.31 per share in the previous quarter outpaced the consensus estimates by 4%. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the full year, analysts expect A to report EPS of $5.59, up 5.7% from $5.29 per share in fiscal 2024. Furthermore, its EPS is expected to grow 8.8% year-over-year to $6.08 in fiscal 2026. A has fallen 8.6% over the past 52 weeks, underperforming both the S&P 500 Index's ($SPX) 14.5% return and the Health Care Select Sector SPDR Fund's (XLV) 8.3% loss over the same time frame. Agilent Technologies reported impressive Q2 performance on May 28, and its shares surged 2.2% in the following trading session. Due to growth in its life sciences and diagnostics markets revenue and a rise in CrossLab segment's sales, the company's overall revenue improved 6% year-over-year to $1.7 billion, topping consensus estimates by 2.5%. Moreover, its adjusted EPS of $1.31 advanced 7.4% from the prior-year quarter, exceeding Wall Street expectations by 4%. A's effective Ignite Transformation initiative supported its Q2 results. Looking ahead to fiscal 2025, A expects revenue to range between $6.7 and $6.8 billion, and projects adjusted EPS in the range of $5.54 to $5.61. Wall Street analysts are moderately optimistic about A's stock, with an overall "Moderate Buy" rating. Among 16 analysts covering the stock, eight recommend "Strong Buy," and eight advise 'Hold.' The mean price target for A is $138.57, indicating a 16% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store